

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Kurosawa S, Yamaguchi T, <u>Uchida N</u> , Miyawaki S, Usuki K, Watanabe M, Yamashita T, Kanamori H, Tomiyama J, Nawa Y, Yano S, Takeuchi J, Yakushiji K, Sano F, Uoshima N, Yano T, Nannya Y, Moriuchi Y, Miura I, Takaue Y, Fukuda T.	Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission.	Biology of Blood and Marrow Transplantation	17	401-411	2011
Tanimoto T, <u>Uchida N</u> , Kodama Y, Teshima T, Taniguchi S.	Safety of workers at the Fukushima Daiichi nuclear power plant.	Lancet	377 (9776)	1489-90	2011
Takagi S, Ota Y, <u>Uchida N</u> , Takahashi K, Ishiwata K, Tsuji M, Yamamoto H, Asano-Mori Y, Matsuno N, Masuoka K, Wake A, Miyakoshi S, Ohashi K, Taniguchi S.	Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis.	Blood	116(4)	649-52	2010
Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, <u>Uchida N</u> , Suzuki N, Sone A, Najima Y, Ozawa H, Wake A, Taniguchi S, Shultz LD, Ohara O, Ishikawa F.	Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML.	Sci Transl Med	2(17)	17-19	2010
Nishida A, Yamamoto H, Ohta Y, Karasawa M, Kato D, <u>Uchida N</u> , Wake A, Taniguchi S.	T-cell post-transplant lymphoproliferative disorder in a patient with chronic idiopathic myelofibrosis following allogeneic PBSC transplantation.	Bone Marrow Transplant	45(8)	1372-1374	2010

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Espinoza JL, Takami A, Onizuka M, Morishima Y, Fukuda T, Kodera Y, Akiyama H, Miyamura K, Mori T, <u>Nakao S.</u>	The recipient PTPN22 – 1123C/C genotype predicts acute graft-versus-host disease after HLA-fully-matched unrelated bone marrow transplantation for hematologic malignancies.	Biol Blood Marrow Transplant	19(2)	240-6	2013
Ishiyama K, Okumura H, Yamazaki H, Kondo Y, Waseda Y, Kotani T, Takami A, <u>Nakao S.</u>	Intensive chemotherapy for a relapsed ALL patient who received living-donor lobar lung Transplantation.	Bone Marrow Transplant	47(1)	135-6	2012
Ishiyama K, Katagiri T, Ohata K, Hosokawa K, Kondo Y, Yamazaki H, Takami A, <u>Nakao S.</u>	Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation.	Transpl Infect Dis	14(1)	33-9	2012
Ishiyama K, Takami A, Kanda Y, <u>Nakao S.</u> , Hidaka M, Maeda T, Naoe T, Taniguchi S, Kawa K, Nagamura T, Atsuta Y, Sakamaki H.	Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis.	Leukemia	26(3)	461-4	2012
Ishiyama K, Takami A, Kanda Y, <u>Nakao S.</u> , Hidaka M, Maeda T, Naoe T, Taniguchi S, Kawa K, Nagamura T, Tabuchi K, Atsuta Y, Sakamaki H.	Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant.	Leukemia	26(6)	1416-9	2012
Hosokawa K, Yamazaki H, Nishitsuji M, Kobayashi S, Takami A, Fujimura M, <u>Nakao S.</u>	Pulmonary veno-occlusive disease following reduced-intensity allogeneic bone marrow transplantation for acute myeloid leukemia.	Intern Med	51(2)	195-8	2012
Espinoza JL, Takami A, Yoshioka K, Nakata K, Sato T, Kasahara Y, <u>Nakao S.</u>	Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions.	Haematologica	97(9)	1295-303	2012

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Ohata K, Yamazaki H, Asakura H, Shimadoi S, <u>Nakao S.</u>	Tamibarotene-induced low-grade reversible intravascular coagulation in a patient with acute promyelocytic leukemia.	Thromb Res	129(2)	213-4,	2012
Espinoza LJ, Takami A, Nakata K, Yamada K, Onizuka M, Kawase T, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue M, Fukuda T, Morishima Y, Kodera Y, <u>Nakao S.</u>	Genetic variants of human granzyme B predict transplant outcomes after HLA matched unrelated bone marrow transplantation for myeloid malignancies.	PLoS One	6(8)	e23827	2011
Ohata K, Iwaki N, Kotani T, Kondo Y, Yamazaki H, <u>Nakao S.</u>	An Epstein-Barr virus-associated leukemic lymphoma in a patient treated with rabbit antithymocyte globulin and cyclosporine for hepatitis-associated aplastic anemia.	Acta Haematol	127	96-99	2011
Katagiri T, Sato-Otsubo A, Kashiwase K, Morishima S, Sato Y, Mori Y, Kato M, Sanada M, Morishima Y, Hosokawa K, Sasaki Y, Ohtake S, Ogawa S, <u>Nakao S.</u>	Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia.	Blood	15:118 (25)	6601-9	2011
Yamaguchi M, Kurokawa T, Ishiyama K, Aoki G, Ueda M, Matano S, Takami A, Yamazaki H, Sawazaki A, Yamauchi H, Yoshida T, <u>Nakao S.</u>	Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.	Ann Hematol	90(10)	1209-17	2011
Kasahara I, Nishio M, Endo T, Fujimoto K, Koike T, Sugimori N, Katagiri T, <u>Nakao S.</u>	Sustained trilineage hematopoietic recovery in a patient with refractory anemia, del(13)(q12q22), and paroxysmal nocturnal hemoglobinuria-type cells treated with immunosuppressive therapy.	Leuk Res	35(9)	e147-8	2011

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Uchida T, Ogawa Y, Kobayashi Y, Ishikawa T, Ohashi H, Hata T, Usui N, Taniwaki M, Ohnishi K, Akiyama H, Ozawa K, Ohyashiki K, Okamoto S, Tomita A, <u>Nakao S</u> , Tobinai K, Ogura M, Ando K, Hotta T.	Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes.	Cancer Sci	102(9)	1680-6	2011
Takamatsu H, Yagasaki H, Takahashi Y, Hama A, Saikawa Y, Yachie A, Koizumi S, Kojima S, <u>Nakao S</u> .	Aplastic anemia successfully treated with rituximab: the possible role of aplastic anemia-associated autoantibodies as a marker for response.	Eur J Haematol	86(6)	541-5	2011
Sekiya A, Morishita E, Karato M, Maruyama K, Shimogawara I, Omote M, Wakugawa Y, Shinohara M, Hayashi T, Kadohira Y, Asakura H, <u>Nakao S</u> , Ohtake S.	Two case reports of inherited antithrombin deficiency: a novel frameshift mutation and a large deletion including all seven exons detected using two methods.	Int J Hematol	93(2)	216-9	2011
Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, <u>Nakao S</u> , Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M.	Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.	Int J Hematol	93(1)	36-46	2011
Katagiri T, Qi Z, Ohtake S, <u>Nakao S</u> .	GPI-anchored protein-deficient T cells in patients with aplastic anemia and low-risk myelodysplastic syndrome: implications for the immunopathophysiology of bone marrow failure.	Eur J Haematol	86(3)	226-36	2011
Espinoza JL, Takami A, Onizuka M, Kawase T, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue M, Ohtake S, Fukuda T, Morishima Y, Kodera Y, <u>Nakao S</u> .	A single nucleotide polymorphism of IL-17 gene in the recipient is associated with acute GVHD after HLA-matched unrelated BMT.	Bone Marrow Transplant	46(11)	1455-63	2011

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Ohata K, Espinoza JL, Lu X, Kondo Y, <u>Nakao S.</u>	Mycophenolic acid inhibits NK cell proliferation and cytotoxic function: A possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen.	Biol Blood Marrow Transplant	17(2)	205-213	2011
Takami A, Espinoza JL, Onizuka M, Ishiyama K, Kawase T, Kanda Y, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue M, Ohtake S, Fukuda T, Morishima Y, Kodera Y, <u>Nakao S.</u>	A single-nucleotide polymorphism of the Fcγ receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies.	Bone Marrow Transplant	46(2)	238-243	2011
Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, <u>Nakao S.</u> Motoyama N, Hirao A.	TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.	Nature	463 (7281)	676-80	2010
Lu X, Ohata K, Kondo Y, Espinoza JL, Qi Z, <u>Nakao S.</u>	Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytotoxicity.	Cancer Sci	101(3)	609-15	2010

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Nishikawa T, Miyahara E, Horiuchi M, Izumo K, Okamoto Y, Kawai Y, <u>Kawano Y</u> , Takeuchi T.	Benzene Metabolite 1,2,4-Benzenetriol Induces Halogenated DNA and Tyrosines Representing Halogenative Stress in the HL-60 Human Myeloid Cell Line.	Environ Health Perspect	120(1)	62-67	2012
Kodama Y, Okamoto Y, Hashiguchi T, Shinkoda Y, Nishikawa T, Tanabe T, <u>Kawano Y</u> .	Vascular endothelial growth factor corrected by the platelet count and hematocrit is associated with the clinical course of aplastic anemia in children.	Int J Hematol	95	494-499	2012
Nishikawa T, Inagaki J, Nagatoshi Y, Fukano R, Nakashima K, Ito N, Sawa D, <u>Kawano Y</u> , Okamura J.	The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: Long-term outcomes.	Pediatr Transplant	16(7)	722-8	2012
Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Kakihana Y, Goto M, <u>Kawano Y</u> .	Acute respiratory distress syndrome as an initial presentation of hemophagocytic lymphohistiocytosis after induction therapy for acute myeloid leukemia.	Pediatr Hematol Oncol.	28(3)	244-248	2011
Nishikawa T, Izumo K, Miyahara E, Horiuchi M, Okamoto Y, <u>Kawano Y</u> , Takeuchi T.	Benzene Induces Cytotoxicity without Metabolic Activation.	J Occup Health	53	84-92	2011
Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Higashi M, Hirano H, Arita K, <u>Kawano Y</u> .	Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation.	Bone Marrow Transplant	45(3)	602-604	2010

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Nagatoshi Y, Matsuzaki A, Suminoe A, Inada H, Ueda K, Kawakami K, Yanai F, Nakayama H, Moritake H, Itonaga N, Hotta N, Fujita K, Hidaka Y, Yamanaka T, <u>Kawano Y</u> , Okamura J.	Randomized Trial to Compare LSA2L2-Type Maintenance Therapy to Daily6-Mercaptopurine and Weekly Methotrexate With Vincristine and Dexamethasone Pulse for Children With Acute Lymphoblastic Leukemia.	Pediatr Blood Cancer	55	239-247	2010
Yamashita T, Kodama Y, Tanaka M, Yamakiri K, <u>Kawano Y</u> , Sakamoto T.	Steroid-induced glaucoma in children with acute lymphoblastic leukemia, a possible complication.	J Glaucoma	19	188-190	2010
Okamoto Y, Kodama Y, Nishikawa T, Yamaki Y, Mougi H, Masamoto I, Tanabe T, Shinkoda Y, <u>Kawano Y</u>	Successful bone marrow transplantation for children with aplastic anemia based on a best-available evidence strategy.	Pediatr Transplant	14	980-5	2010

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Tamai H, Miyake K, <u>Yamaguchi H</u> , Takatori M, Dan K, Inokuchi K, Shimada T.	AAV-8 vector expressing IL-24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice.	Blood	5:119 (1)	64-71	2012
<u>Yamaguchi H</u> , Wakita S, Miyake K, Mitamura Y, Kosaka F, Dan K, Inokuchi K.	Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.	Leukemia	25(9)	1423-32	2011
<u>Yamaguchi H</u> , Hirakawa T, Inokuchi K.	Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma.	J Clin Exp Hematop	51(1)	1-5	2011
Hirakawa T, <u>Yamaguchi H</u> , Mitamura Y, Kosaka F, Dan K, Inokuchi K.	No racial difference in allele frequencies of FCGR3A gene F158V polymorphisms in diffuse large B-cell lymphoma.	Eur J Haematol	86(2)	180-1	2011
Tamai H, Miyake K, <u>Yamaguchi H</u> , Takatori M, Dan K, Inokuchi K, Shimada T.	Resistance of MLL-AFF1-positive acute lymphoblastic leukemia to tumor necrosis factor-alpha is mediated by S100A6 up-regulation.	Blood Cancer Journal	1(11)	e38	2011
Inokuchi K, Wakita S, Hirakawa T, Tamai H, Yokose N, <u>Yamaguchi H</u> , Dan K.	RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.	Int J Hematol	94(3)	255-60	2011
Tamai H, Miyake K, Takatori M, Miyake N, <u>Yamaguchi H</u> , Dan K, Shimada T, Inokuchi K.	Activated K-Ras protein accelerates human MLL/AF4-induced leukemo- lymphomogenicity in a transgenic mouse model.	Leukemia	25(5)	888-91	2011

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
<u>Yamaguchi H</u> , Inokuchi K, Takeuchi J, Tamai H, Mitamura Y, Kosaka F, Ly H, Dan K.	Identification of TNF2 gene mutations in adult Japanese patients with acquired bone marrow failure syndromes.	Br J Haematol	150(6)	725-7	2010
Tajika K, <u>Yamaguchi H</u> , Mizuki T, Nakamura H, Nakayama K, Dan K.	Stem cell transplantation using non-myeloablative conditioning regimen with fludarabine for hematological malignancies.	J Nippon Med Sch	77(5)	254-9	2010
Hirakawa T, <u>Yamaguchi H</u> , Yokose N, Gomi S, Inokuchi K, Dan K.	Importance of maintaining the relative dose intensity of CHOP- like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.	Ann Hematol	89(9)	897-904	2010

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Tada K, Kim SW, Asakura Y, Hiramoto N, Yakushijin K, Kurosawa S, Tajima K, <u>Mori S</u> , Heike Y, Tanosaki R, Maeshima AM, Taniguchi H, Furuta K, Kagami Y, Matsuno Y, Tobinai K, Takaue Y, Fukuda T.	Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.	Am J Hematol	87	770-775	2012
Okita Y, Narita Y, Miyakita Y, Ohno M, Aihara K, <u>Mori S</u> , Kayama T, Shibui S.	Reactivation of cytomegalovirus following treatment of malignant glioma with temozolomide.	Int Canc Conf J	1	53-57	2012
Fuji S, Nakamura F, Hatanaka K, Taniguchi S, Sato M, <u>Mori S</u> , Sakamaki H, Yabe H, Miyamoto T, Kanamori H, Ueda Y, Kawa K, Kato K, Suzuki R, Atsuta Y, Tamaki T, Kanda Y.	Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: A retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	18(9)	1407-14	2012
Araoka H, Baba M, Tateda K, Ishii Y, Oguri T, Okuzumi K, Oishi T, <u>Mori S</u> , Mitsuda T, Moriya K, Nakamori Y, Ohmagari N, Yamaguchi K, Yoneyama A.	In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan.	Jpn J Infect Dis	65	84-87	2012
Yokoyama H, <u>Mori S</u> , Kobayashi Y, Kurosawa S, Saito B, Fuji S, Maruyama D, Azuma T, Kim SW, Watanabe T, Tanosaki R, Tobinai K, Takaue Y, Fukuda T.	Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients.	Int J Hematol	92(2)	334-41	2010
Morita-Hoshi Y, <u>Mori S</u> , Soeda A, Wakeda T, Ohsaki Y, Shiwa M, Masuoka K, Wake A, Taniguchi S, Takaue Y, Heike Y.	Identification of molecular markers for pre-engraftment immune reactions after cord blood transplantation by SELDI-TOF MS.	Bone Marrow Transplant	45(11)	1594-601	2010

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Nagafuji K, Matsuo K, Teshima T, <u>Mori S</u> , Sakamaki H, Hidaka M, Ogawa H, Koderu Y, Kanda Y, Maruta A, Mori T, Yoshida F, Ichinohe T, Kasai M, Takatsuka Y, Kubo K, Sao H, Atsuta Y, Suzuki R, Yoshida T, Tsuchida M, Harada M.	Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry.	Int J Hematol	91(5)	855-64	2010
Kanda Y, Yamashita T, Mori T, Ito T, Tajika K, <u>Mori S</u> , Sakura T, Hara M, Mitani K, Kurokawa M, Akashi K, Harada M.	A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT.	Bone Marrow Transplant	45(8)	1325-32	2010
Kakugawa Y, Kami M, Matsuda T, Saito Y, Kim SW, Fukuda T, <u>Mori S</u> , Shimoda T, Tanosaki R, Saito D.	Endoscopic diagnosis of cytomegalovirus gastritis after allogeneic hematopoietic stem cell transplantation.	World J Gastroenterol	16 (23)	2907-12	2010

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Oshima K, Kanda Y, Nanya Y, Tanaka M, Nakaseko C, <u>Yano S</u> , Fujisawa S, Fujita H, Yokota A, Takahashi S, Kanamori H, Okamoto S; for the Kanto Study Group for Cell Therapy (KSGCT).	Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatine clearance before transplantation.	Ann Hematol	92(2)	255-60	2013
Yanada M, Kurosawa S, Yamaguchi T, Uchida N, Miyawaki S, Kanamori H, Usuki K, Kobayashi T, Watanabe M, Nagafuji K, <u>Yano S</u> , Nawa Y, Tomiyama J, Tashiro H, Nakamura Y, Fujisawa S, Kimura F, Emi N, Miura I, Fukuda T.	Effect of related donor availability on outcome of AML in the context of related and unrelated hematopoietic cell transplantation.	Bone Marrow Transplant	48(3)	390-5	2013
Shimizu H, Saitoh T, Tanaka M, Mori T, Sakura T, Kawai N, Kanda Y, Nakaseko C, <u>Yano S</u> , Fujita H, Fujisawa S, Miyawaki S, Kanamori H, Okamoto S.	Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma.	Leukemia	26(12)	2469-73	2012
Usuki K, Kurosawa S, Uchida N, Yakushiji K, Waki F, Matsuishi E, Kagawa K, Furukawa T, Maeda Y, Shimoyama M, Ago H, Yamano Y, <u>Yano S</u> , Fujishima N, Takamatsu Y, Eto T, Hidaka M, Matsuoka H, Fukuda T.	Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission.	Clin Lymphoma Myeloma Leuk	12	444-451	2012
<u>Yano S</u> , Minami J, Nishiwaki K, Shimada T, Dobashi N, Yahagi Y, Takei Y, Takahara S, Ogasawara Y, Sugiyama K, Yamaguchi Y, Saito T, Kasama K, Yokoyama H, Machishima T, Katsube A, Usui N, Aiba K.	Rapid progression and unusual premortal diagnosis of mucormycosis in patients with hematologic malignancies: analysis of eight patients.	Int J Hematol	93	344-50	2011

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Kanamori H, Usuki K, Yamashita T, Watanabe M, Yakushiji K, <u>Yano S</u> , Nawa Y, Taguchi J, Takeuchi J, Tomiyama J, Nakamura Y, Miura I, Kanda Y, Takaue Y, Fukuda T.	A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission.	Blood	117	2113-2120	2011
Kurosawa S, Yamaguchi T, Uchida N, Miyawaki S, Usuki K, Watanabe M, Yamashita T, Kanamori H, Tomiyama J, Nawa Y, <u>Yano S</u> , Takeuchi J, Yakushiji K, Sano F, Uoshima N, Yano T, Nannya Y, Moriuchi Y, Miura I, Takaue Y, Fukuda T.	Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission.	Biol Blood Marrow Transplant	17	401-411	2011
Dobashi N, Usui N, <u>Yano S</u> , Yahagi Y, Takei Y, Sugiyama K, Takahara S, Ogasawara Y, Yamaguchi Y, Saito T, Yokoyama H, Aiba K.	Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.	Jpn J Clin Oncol	41	820-824	2011
Minami J, Dobashi N, Asai O, <u>Yano S</u> , Osawa H, Takei Y, Yahagi Y, Takahara S, Ogasawara Y, Yamaguchi Y, Kobayashi T, Morikawa N, Nikaido T, Aiba K, Usui N.	Two cases of mediastinal gray zone lymphoma.	J Clin Exp Hematop	50	143-149	2010
Nakasone H, Kanda Y, Takasaki H, Nakaseko C, Sakura T, Fujisawa S, Yokota A, <u>Yano S</u> , Usuki K, Maruta A, Abe D, Hoshino T, Takahashi S, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy.	Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia.	Leukemia	24	1236-1239	2010

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Imagawa J, Tanaka H, <u>Matsumoto K</u> , Morita K, Harada Y, Harada H.	A sharp fluctuation in peripheral blood cells shortly after dasatinib administration.	Int J Hematol	96	194-199	2012
Hiraki Y, Tsuji Y, Hiraike M, Misumi N, <u>Matsumoto K</u> , Morita K, Kamimura H, Karube Y.	Correlation between serum linezolid concentration and the development of thrombocytopenia.	Scand J Infect Dis	44(1)	60-4	2012
Tsuji Y, Hiraki Y, <u>Matsumoto K</u> , Mizoguchi A, Sadoh S, Kobayashi T, Takemura Y, Sakamoto S, Morita K, Kamimura H, Karube Y.	Pharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post-neurosurgical bacterial meningitis.	Scand J Infect Dis	43 (11-12)	982-5	2011
Hiraki Y, Tsuji Y, <u>Matsumoto K</u> , Morita K, Kamimura H, Karube Y.	Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin.	Am J Med Sci	342(6)	456-60	2011
Tsuji Y, Hiraki Y, <u>Matsumoto K</u> , Mizoguchi A, Kobayashi T, Sadoh S, Morita K, Kamimura H, Karube Y.	Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction.	J Infect Chemother	17(1)	70-5	2011
Ogura T, Kajiume T, Sera Y, Kawaguchi H, Kobatake M, Okamoto N, Ohtsuka Y, <u>Matsumoto K</u> , Morita K, Kobayashi T, Ohdan H, Kobayashi M.	Hepatic arterial infusion of liposomal amphotericin B for multiple fungal abscesses in the liver of a patient with chronic granulomatous disease.	Rinsho Ketsueki	51(5)	345-8	2010
Watanabe A, <u>Matsumoto K</u> , Igari H, Uesato M, Yoshida S, Nakamura Y, Morita K, Shibuya K, Matsubara H, Yoshino I, Kamei K.	Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome).	Int J Infect Dis	14 Suppl 3	e220-3	2010

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
Hatanaka R, Obara T, <u>Watabe D</u> , Ishikawa T, Kondo T, Ishikura K, Aikawa T, Aono Y, Hara A, Metoki H, Asayama K, Kikuya M, Mano N, Ohkubo T, Izumi S, Imai Y.	Association of arterial stiffness with silent cerebrovascular lesions: the Ohasama study.	Cerebrovasc Dis	31	329-337	2011
Hatanaka R, Obara T, <u>Watabe D</u> , Kimura A, Hanazawa T, Ohba H, Ishikawa T, Aikawa T, Hara A, Metoki H, Asayama K, Kikuya M, Ohkubo T, Totsune K, Imai Y.	Individual assessment of inherent arterial stiffness using nomogram and pulse wave velocity index: the Ohasama study.	Clin Exp Hypertens	33	147-152	2011

著者名 (研究者にアンダーライン)	論文タイトル	発表誌名	巻号	ページ	出版年
<u>Kurosawa S</u> , Yamaguchi T, Uchida N, Miyawaki S, Usuki K, Watanabe M, Yamashita T, Kanamori H, Tomiyama J, Nawa Y, Yano S, Takeuchi J, Yakushiji K, Sano F, Uoshima N, Yano T, Nannya Y, Moriuchi Y, Miura I, Takaue Y, Fukuda T.	Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission.	Biol Blood Marrow Transplant	17(3)	401-11	2011
<u>Kurosawa S</u> , Yamaguchi T, Miyawaki S, Uchida N, Kanamori H, Usuki K, Yamashita T, Watanabe M, Yakushiji K, Yano S, Nawa Y, Taguchi J, Takeuchi J, Tomiyama J, Nakamura Y, Miura I, Kanda Y, Takaue Y, Fukuda T.	A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission.	Blood	117(7)	2113-2120	2011
<u>Kurosawa S</u> , Yamaguchi T, Uchida N, Miyawaki S, Usuki K, Watanabe M, Yamashita T, Kanamori H, Tomiyama J, Nawa Y, Yano S, Takeuchi J, Yakushiji K, Sano F, Uoshima N, Yano T, Nannya Y, Moriuchi Y, Miura I, Takaue Y, Fukuda T.	Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission.	Biol Blood Marrow Transplant	17(3)	401-411	2011
<u>Kurosawa S</u> , Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, Usuki K, Yamashita T, Okoshi Y, Shibayama H, Nakamae H, Mawatari M, Hatanaka K, Sunami K, Shimoyama M, Fujishima N, Maeda Y, Miura I, Takaue Y, Fukuda T.	Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.	Haematologica	95(11)	1857-64	2010
Yokoyama H, Mori SI, Kobayashi Y, <u>Kurosawa S</u> , Saito B, Fuji S, Maruyama D, Azuma T, Kim SW, Watanabe T, Tanosaki R, Tobinai K, Takaue Y, Fukuda T.	Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients.	Int J Hematol	92(2)	334-341	2010

IV. 研究成果の刊行物（論文別刷）

Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission

Masamitsu Yanada,¹ Saiko Kurosawa,² Takuhiro Yamaguchi,³ Takuya Yamashita,² Yukiyoichi Moriuchi,⁴ Hiroatsu Ago,⁵ Jin Takeuchi,⁶ Hirohisa Nakamae,⁷ Jun Taguchi,⁸ Toru Sakura,⁹ Yasushi Takamatsu,¹⁰ Fusako Waki,¹¹ Hiroki Yokoyama,¹² Masato Watanabe,¹³ Nobuhiko Emi,¹ and Takahiro Fukuda²

¹Department of Hematology, Fujita Health University, Aichi; ²Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo; ³Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi; ⁴Department of Hematology, Sasebo City General Hospital, Nagasaki; ⁵Department of Hematology and Oncology, Shimane Prefectural Central Hospital, Shimane; ⁶Department of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo; ⁷Hematology, Osaka City University, Osaka; ⁸Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; ⁹Department of Hematology, Saiseikai Maebashi Hospital, Gunma; ¹⁰Division of Medical Oncology, Hematology and Infectious Disease, Department of Medicine, Fukuoka University Hospital, Fukuoka; ¹¹Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa; ¹²Division of Clinical Oncology and Hematology, Jikei University School of Medicine, Tokyo; and ¹³Division of Hematology, Yamada Hospital, Gifu, Japan

ABSTRACT

To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first complete remission was 14% at four years, which was significantly lower than that reported in patients without monosomal karyotype, primarily due to a high relapse rate (86%). Monosomal karyotype remained significantly associated with worse overall survival among patients with unfavorable cytogenetics or complex karyotype, and even in patients who underwent allogeneic hematopoietic cell transplantation during first complete remission. These findings confirm that monosomal karyotype has a significantly adverse effect on post-remission outcome in patients with acute myeloid leukemia treated with and without allogeneic hematopoietic cell transplantation in first complete remis-

sion, emphasizing the need for the development of alternative therapies for this patient population.

Key words: acute myeloid leukemia, monosomal karyotype, cytogenetics, post-remission therapy, allogeneic hematopoietic cell transplantation.

Citation: Yanada M, Kurosawa S, Yamaguchi T, Yamashita T, Moriuchi Y, Ago H, Takeuchi J, Nakamae H, Taguchi J, Sakura T, Takamatsu Y, Waki F, Yokoyama H, Watanabe M, Emi N, and Fukuda T. Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. *Haematologica* 2012;97(6):915-918. doi:10.3324/haematol.2011.058289

©2012 Ferrata Storti Foundation. This is an open-access paper.

Introduction

Acute myeloid leukemia (AML) is a heterogeneous disease that includes subsets with distinct biological, clinical and prognostic features. It has been well established that cytogenetic abnormalities at diagnosis are associated with the biology of the disease and have important prognostic implications.¹⁻³ The coexistence of multiple cytogenetic abnormalities designated as complex karyotype (CK) has been recognized as a factor that predicts an extremely unfavorable outcome in AML.^{4,7} However, the prognostic significance of CK has recently been challenged by Breems *et al.* who showed that the monosomal karyotype (MK), defined as 2 or more distinct autosomal monosomies or a single autosomal monosomy in the presence of other structural abnormalities,

adversely affects the prognosis, and that the overlap of MK with CK is the main contributor to the unfavorable impact of CK.⁸ According to Breems *et al.* and reports published subsequently by other groups,⁷⁻¹⁰ patients with MK⁺ AML show low complete remission (CR) rates ranging from 18% to 48% and overall survival (OS) rates of less than 10%. On the other hand, it has been suggested that such a poor outcome may be improved by allogeneic hematopoietic cell transplantation (HCT).¹¹

To further clarify the prognosis of patients with MK⁺ AML, especially regarding outcome after allogeneic HCT during first CR (CR1), we performed a retrospective analysis by using a dataset that included more than 2,000 AML patients in CR. Since failure to achieve CR is obviously associated with a dismal prognosis regardless of the presence or absence

The online version of this article has a Supplementary Appendix.

Acknowledgments: this work was supported by grants from the Japanese Ministry of Health, Labour and Welfare and the Advanced Clinical Research Organization.

Manuscript received on November 8, 2011. Revised version arrived on December 13, 2011. Manuscript accepted on December 15, 2011.

Correspondence: Saiko Kurosawa, MD, Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Phone international: +81.3.35422511; Fax international: +81.3.35423815; E-mail: skurosaw@ncc.go.jp

of MK, the present analysis focused on patients who achieved CR with one or two courses of chemotherapy.

Design and Methods

Patients

For this study, we used a Japanese nationwide database of adult AML patients. Eligible patients were required to be between 16 and 70 years of age, to be diagnosed with AML from 1999 to 2006 according to the World Health Organization (WHO) classification,¹² and to have achieved CR with one or two courses of chemotherapy. We excluded patients with acute promyelocytic leukemia (n=386) and those without pre-treatment cytogenetic results (n=36); this left 2,099 patients available for analysis. This study was approved by the Institutional Review Board at the National Cancer Center Hospital.

Cytogenetic analysis

Cytogenetic analysis was performed on metaphases from samples of bone marrow or blood obtained prior to induction therapy by using standard banding techniques. Karyotypes were determined according to the International System for Human Cytogenetic Nomenclature.¹³ An abnormality was considered to be clonal when at least 2 metaphases had the same aberration in the case of either a structural abnormality or an additional chromosome. If there was a monosomy, it had to be present in at least 3 metaphases to be considered significant. Cytogenetics was classified as favorable, intermediate, unfavorable or unknown risk according to the Southwest Oncology Group (SWOG) criteria.⁵ Apart from the SWOG classification, the MK status was assessed retrospectively for this study according to the definition proposed by Breems *et al.*⁸ Accordingly, patients were divided into 4 cytogenetic subgroups: core binding factor AML (CBF AML), cytogenetically normal AML (CN AML), cytogenetically abnormal non-CBF AML without MK (MK⁻ AML), and cytogenetically abnormal non-CBF AML with MK (MK⁺ AML).

Statistical analysis

A Kaplan-Meier survival analysis was performed to estimate the probabilities of OS and relapse-free survival (RFS). OS was defined as the time from the achievement of first CR (CR1) to death or last visit, and RFS as the time from the achievement of CR1 to relapse, death or last visit. Differences in OS and RFS between groups were compared by means of the log rank test. Cumulative incidences of relapse and non-relapse mortality were calculated with relapse considered as a competing risk for non-relapse mortality, and vice versa. Cox's regression model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical analyses were performed with the SPSS software version 11.0.1 (SPSS, Chicago, IL, USA) and R software version 2.13.0 (The R Foundation for Statistical Computing).

Results and Discussion

The entire cohort consisted of 2,099 AML patients who had achieved CR with one or two courses of chemotherapy, among whom CBF AML, CN AML, MK⁻ AML and MK⁺ AML accounted for 21%, 49%, 27% and 4%, respectively. Table 1 shows the patients' characteristics according to these cytogenetic subgroups. Among the 73 patients with MK⁺ AML, 68 (93%) had a cytogenetically unfavorable risk, while the remaining 5 had an unknown risk. In patients younger than 60 years, intensive therapy defined as "3+7" or its equivalent, was given to more than 95% in all of the

cytogenetic subgroups. In patients aged 60 years or older, the proportion of those given intensive therapy seemed slightly lower in MK⁺ AML but, nevertheless, 75% of them received intensive therapy.

Allogeneic HCT was performed in 32 patients with MK⁺ AML, including 15 during CR1, 4 during second CR (CR2) and 13 during other disease phases. The details of patients who underwent allogeneic HCT in CR1 are summarized in the *Online Supplementary Table S1*. The median time from CR1 to transplantation was 93 days (range 14-540 days) for the 15 patients with MK⁺ AML, which was significantly shorter than those in the other groups ($P=0.011$).

Figure 1A compares survival curves from the time of CR1 according to the cytogenetic subgroups. With a median follow up of 4.1 years for surviving patients, the 4-year probabilities of OS were 68% in CBF AML, 58% in CN AML, 46% in MK⁻ AML and 14% in MK⁺ AML, respectively ($P<0.001$). This significantly inferior OS in MK⁺ AML patients can mainly be explained by a high risk of relapse, since the relapse rate was 86% at four years, which was significantly higher than those in the remaining groups ($P<0.001$). No patient with MK⁺ AML survived four years without allogeneic HCT, and the difference in OS was more pronounced when patients undergoing allogeneic HCT were analyzed as censored cases (83%, 66%, 54% and 0% at four years in CBF AML, CN AML, MK⁻ AML and MK⁺ AML, respectively; $P<0.001$).

Next, we examined whether MK identified a very poor prognostic subset within 2 cytogenetically distinct subpopulations representing poor prognosis, i.e. unfavorable cyto-

Table 1. Patient's characteristics according to cytogenetic subgroup.

	CBF n=437	CN n=1,027	MK ⁻ n=562	MK ⁺ n=73
Age, years				
Median	45	51	48	53
Range	16-70	16-70	16-70	20-70
Sex				
Male	279 (64%)	576 (56%)	311 (55%)	47 (64%)
Female	158 (36%)	451 (44%)	251 (45%)	26 (36%)
Cytogenetic risk by SWOG				
Favorable	411 (94%)	-	-	-
Intermediate	-	1,027 (100%)	64 (11%)	-
Unfavorable	26 (6%)	-	300 (53%)	68 (93%)
Unknown	-	-	198 (35%)	5 (7%)
WBC count, $\times 10^9/L$				
Median	11.2	13.0	8.5	4.4
Range	0.7-281.2	0.4-40.2	0.3-22.3	0.8-408.0
Dysplasia				
Yes	35 (8%)	220 (20%)	136 (24%)	33 (45%)
No	402 (92%)	807 (80%)	426 (76%)	40 (55%)
N. induction courses				
1 course	378 (86%)	825 (80%)	419 (75%)	56 (77%)
2 courses	59 (14%)	202 (20%)	143 (25%)	17 (23%)
Allogeneic HCT				
CR1	32 (7%)	256 (25%)	183 (33%)	15 (21%)
CR2	78 (18%)	106 (10%)	57 (10%)	4 (5%)
Other disease phase	66 (15%)	125 (12%)	87 (15%)	13 (18%)
Not performed	261 (60%)	540 (53%)	235 (42%)	41 (56%)

CBF: core binding factor AML; CN: cytogenetically normal AML; MK⁻: cytogenetically abnormal non-CBF AML without monosomal karyotype; MK⁺: cytogenetically abnormal non-CBF AML with monosomal karyotype; SWOG: Southwest Oncology Group; WBC: white blood cell count; HCT: hematopoietic cell transplantation; CR1: first complete remission; CR2: second complete remission.




Figure 1. Kaplan-Meier curves for (A) OS after achieving CR1 for the entire cohort, and for (B) OS after allogeneic HCT for patients who underwent allogeneic HCT in CR1, according to the cytogenetic subgroups. CBF represents core binding factor AML; CN: cytogenetically normal AML; MK-, cytogenetically abnormal non-CBF AML without monosomal karyotype; MK+, cytogenetically abnormal non-CBF AML with monosomal karyotype. P values are presented for comparisons among the 4 groups.

genetics and CK. MK accounted for 17% of those with unfavorable cytogenetics (68 of 394), and 41% of those with CK (39 of 96). Among patients with unfavorable cytogenetics, there was a statistically significant difference in OS between those with and without MK (16% vs. 46% at four years, $P < 0.001$; *Online Supplementary Figure S1A*). Similar findings were seen in patients with CK, with 4-year OS rates of 11% and 34% in those with and without MK ($P < 0.001$; *Online Supplementary Figure S1B*).

Allogeneic HCT was performed during CR1 in 32 of 437 CBF AML patients (7%), 256 of 1,027 CN AML patients (25%), 183 of 562 MK- AML patients (33%), and 15 of 73 MK+ AML patients (21%). Figure 1B shows Kaplan-Meier curves for OS after HCT in patients who were transplanted during CR1. These subgroups showed significantly different OS, with 4-year OS rates of 61%, 67%, 52% and 31% in CBF AML, CN AML, MK- AML, and MK+ AML, respectively ($P = 0.006$). A statistically significant difference was observed in terms of post-transplant relapse ($P = 0.025$) (*Online Supplementary Table S2*). Non-relapse mortality in patients with MK+ AML appeared to be higher than those in the other groups, but these differences were not statistically significant ($P = 0.595$). Table 2 shows results of univariate and multivariate analyses on factors associated with post-transplant OS in patients undergoing allogeneic HCT in CR1. After adjusting for other covariates, MK remained significantly associated with inferior post-transplant OS (HR 3.12; 95% CI, 1.58-6.15; $P = 0.001$, with reference to CN AML).

MK is a recently proposed subgroup of cytogenetic abnormalities that confers a very unfavorable prognosis in AML.⁸ Reported CR rates have been quite low, ranging between 18 and 48%,^{8,10} and this represents a major cause of the poor prognosis. Since patients who fail to achieve CR generally have a very unfavorable prognosis regardless of the presence or absence of MK, we decided to restrict our analysis to patients who had achieved CR. In our patient population, MK was observed in 4%; this was lower than the values reported previously (6-13%).⁷⁻⁹ The most proba-

Table 2. Factors associated with post-transplant OS in patients who underwent allogeneic HCT in CR1.

	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P	HR (95% CI)	P
Cytogenetic subgroup				
CBF	1.14 (0.62-2.09)	0.671	1.17 (0.63-2.15)	0.622
CN	1.00	-	1.00	-
MK-	1.43 (1.05-1.96)	0.023	1.45 (1.06-1.98)	0.021
MK+	2.74 (1.42-5.28)	0.003	3.12 (1.58-6.15)	0.001
Age				
As a numerical variable (1 year older)	1.01 (1.00-1.02)	0.294	1.01 (0.99-1.02)	0.377
Sex				
Male	1.00	-	1.00	-
Female	1.08 (0.81-1.45)	0.597	1.16 (0.86-1.57)	0.327
WBC count				
As a numerical variable ($10 \times 10^9/L$ lower)	1.02 (1.00-1.03)	0.037	1.02 (1.01-1.04)	0.007
Donor				
Related*	1.00	-	1.00	-
Other	1.39 (1.04-1.87)	0.026	1.47 (1.09-1.98)	0.011
Conditioning				
Myeloablative	1.00	-	1.00	-
Reduced-intensity	1.13 (0.81-1.58)	0.465	1.04 (0.70-1.56)	0.846

HR: hazard ratio; CI: confidence interval; CBF: core binding factor AML; CN: cytogenetically normal AML; MK-: cytogenetically abnormal non-CBF AML without monosomal karyotype; MK+: cytogenetically abnormal non-CBF AML with monosomal karyotype; WBC: white blood cell count. *"Related" indicates a matched or 1 antigen-mismatched family donor.

ble explanation for this could be the fact that our cohort included only patients who had achieved CR, while the other studies included newly diagnosed patients.

Our data clearly demonstrated that MK confers a significantly worse prognosis in patients who have achieved CR. Notably, MK identified patients with a worse prognosis